Skip to main content
SpringerLink
Log in

Hochdosiertes Medroxyprogesteronacetat beim metastasierenden Mammakarzinom: Beziehung zwischen Krankheitsverlauf und Hormonprofilen

High dose medroxyprogesteroneacetate in metastatic breast cancer: Correlations between tumor response and endocrine parameters

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

Based upon preliminary observations that tumor response to MPA was correlated to cortisol suppression 42 patients were treated with MPA at different dose levels. 1 500 mg MPA p.o. almost completely suppressed endogenous cortisol production in 23 out of 23 patients.

Consequently, 51 patients with advanced stage metastatic breast cancer were treated with Medroxyprogesteroneacetate (HD-MAP) at a dosage of 1 500 mg p.o. daily or 500 mg i.m. on 5 days per week. There were 5 complete and 7 partical remissions, 23 patients with no change and 10 with progressive disease. 7 patients were not evaluable. Clinical results correlated to plasma cortisol and prolactin blood levels bot not to LH, FSH, TSH, TBI, T3, T4, ACTH and aldosterone measurements. There was no patient with relapse and suppressed cortisol or normal prolactin measurements. The development of pituituary resistance to MPA is suggested. HD-MPA was equally effective in estrogen and/or progesterone receptor positive as in receptor negative patients. It is proposed that cortisol and prolactin determinations are useful to monitor for effective MPA treatment and the early detection of MPA resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Aldinger K (1978) TSH and prolactin levels in breast cancer. Arch Intern Med 138:1638–1641

    Google Scholar 

  2. Barbieri RL, Osathanoudh R, Ryan KJ (1981) Danazol inhibition of steroidgenesis in the human corpus luteum. Obstet Gynecol 57:722–724

    Google Scholar 

  3. Blossey HC, Bartsch HH, Köbberling J (1980) Binding characteristics of medroxyprogesteroneacetate to steroid receptors in human mamma carcinoma. J Clin Chem Biochem 18:729–730

    Google Scholar 

  4. Blossey HC, Köbberling J (1981) The mechanism of the antitumor activity of medroxyprogesterone acetate in breast cancer. Acta Endocrinol [Suppl] 243 (Abstract 208)

  5. Blossey HC, Bartsch HH, Kanne D, Köbberling J (1982a) The pharmacokinetics of high-dose medroxyprogesterone acctate (MPA) in the therapy of advanced breast cancer. Cancer Chemother Pharmacol 8:77–81

    Google Scholar 

  6. Blossey HC, Wander HE, Kleeberg U, Köbberling J, Nagel GA (1982b) Medroxyprogesteroneacetat in hoher Dosierung beim metastasierenden Mammakarzinom. Vergleichende Klinik, Pharmakokinetik und Pharmakodynamik verschiedener Applikationsformen. Onkologie (Sonderheft zu Band 5) 13–24

  7. Bullock LP, Bardin CW, Sherman MR (1978) Androgenic, antiandrogenic, and synandrogenic actions of progestins. Role of steric and allosteric interactions with androgen receptors. Endocrinology 103:1768–1782

    Google Scholar 

  8. Cortés Funes H, Méndez M, Madrigal PL, Alonso A (1982) Die Behandlung des fortgeschrittencn Brustkrebses mit zwei verschiedenen Dosierungen von Medroxyprogesteron Acetat (MAP). Med Klin (Sondernummer) 2:15–18

    Google Scholar 

  9. De Lena M, Brambilla C, Valagussa P, Bonodonna G (1979) High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 2:175–180

    Google Scholar 

  10. Duax WL, Cody V, Griffin J, Hazel J, Weeks CM (1978) Steroid structure and function: II. Conformational transmission and receptor binding of medroxyprogesterone acetate. J Steroid Biochemistry 9:901–907

    Google Scholar 

  11. Ganzina F, Robustelli della Cuna G (1982) Nebenwirkungen unter der Therapie hormonabhängiger Tumoren mit hochdosiertem Medroxyprogesteron-Acetat (HD-MAP). Med Klin (Sondernummer) 2:11–14

    Google Scholar 

  12. Hayward JC, Carbone PO, Henson JC, Kumaoka S, Segloff A, Reubens RD (1977) Assessment of response to therapy in advanced brcast cancer. Cancer 39:1289–1294

    Google Scholar 

  13. Hellmann L, Yoshida K, Zumoff B, Levin J, Kream J, Fukushima DK (1976) The effect of medroxyprogesterone acetate on the pituitary-adrenanal axis. J Clin Endocrinol Metab 42:912–917

    Google Scholar 

  14. Hesselius IR (1982) Pharmakokinetik und Bioverfügbarkeit von MAP in der Krebsbehandlung. Med Klin (Sondernummer) 2:7–10

    Google Scholar 

  15. Iacobelli S, Longo P, Scambia G, Natori V, Sacco F (1980) Progesterone receptors and hormone sensitivity of human endometrial carcinoma. In: Iacobelli S and Dimarco A (eds) Role of medroxyprogesterone in endocrine-related tumors. Progress in cancer research and therapy, Vol 15. Raven Press, New York, pp 91–106

    Google Scholar 

  16. Iacobelli S, Naboli C, Sica G, Marchetti P (1982) Gemeinsamkeiten und Unterschiede der wachstumshemmenden Wirkung von MAP und Tamoxifen auf östrogenempfindliche menschliche Brustkrebszellen. Med Klin (Sondernummer) 2:3–6

    Google Scholar 

  17. Izuo M, Iino Y, Endo K (1981) Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies. Breast Cancer Res Treatment I:125–130

    Google Scholar 

  18. Kaiser DG, Carlson RG, Kirton KT (1974) GLC determination of medroxyprogesterone acetate in plasma. J Pharmacol Sci 3:420–424

    Google Scholar 

  19. Köbberling J, v. z. Mühlen A (1972) Methodische Untersuchungen zur Bestimmung der Plasmacorticoide mit der Proteinbindungsmethode. Z Klin Chem Klin Biochem 2:67–73

    Google Scholar 

  20. Mattsson W (1978) High-dosc medroxyprogesterone acetate treatment in advanced mammary carcinoma. A phase II investigation. Acta Radiol Oncol 17:387

    Google Scholar 

  21. McGuire WL, Carbone PP, Has ME (1975) Estrogen receptors in breast cancer. In: McGuire WL, Carbone PP, Vollmer PD (eds) Estrogen receptors in human breast cancer. Raven Press, New York

    Google Scholar 

  22. Nagel GA, Wander HE, Blossey HC (1981) Hyperprolactinämie beim metastasierenden Mammakarzinom. Schweiz Med Wochenschr 111:1977–1979

    Google Scholar 

  23. Nagel GA, Holtkamp W, Wander HE, Blossey HC (1982) Hyperprolactinemia and bromocriptine in metastatic breast cancer. 17th Annual Meeting of the American Association for Cancer Research. Proceedings Vol 23, No 548

  24. Pannuti F, Martoni A, Pollutri E, Camera P, Lenaz GR (1974) Medroxyprogesterone acetate (MAP): Effects of massive doses in advanced breast cancer. IRCS Medical Sci 2:1605

    Google Scholar 

  25. Pannuti F, Fruet F, Cricca A (1977a) Pilot trial of the use of massive doses of medroxyprogesterone acetate (MPA) orally. Oncology Obstet Gynecol 5:577

    Google Scholar 

  26. Pannuti F, Martoni A, Piana E (1977b) Higher doses of medroxyprogesterone acetate in the treatment of advanced breast cancer. IRCS Med Sci 5:54

    Google Scholar 

  27. Pannuti F (1979) Die hochdosierte Gestagenbehandlung in der Therapie des fortgeschrittenen Mammakarzinoms. Onkologie 2:54–60

    Google Scholar 

  28. Robustelli della Cuna GR, Alciati A, Strada MRB, Bumma C, Campino L (1978) High-dose medroxyprogesterone acetate (MPA): Treatment in metastatic carcinoma of the breast: A dose response evaluation. Tumori 64:143–149

    Google Scholar 

  29. Sadoff L, Lusk W (1974) The effect of large dosis of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of cortison, T4, LH and Testosterone in patients with advanced cancer. Obstet Gynecol 2:262–266

    Google Scholar 

  30. Tamassia V, Battaglia A, Ganzina F, Isetta AM, Saccherti G, Cavalli F, Goldhirsch A, Brunner K, Bernardo G, Robustelli della Cuna G (1982) Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology. Cancer Chemother Pharmacol 8:151–156

    Google Scholar 

  31. Teulings FAG, van Gilse HA, Henkelmann MS, Portengen H, Alexieva-Figusch J (1980) Estrogen, androgen, glucocorticoid, and progesterone receptors in prog-stin-induced regression of human breast cancer. Cancer Res 40:2557–2561

    Google Scholar 

  32. Wander HE, Bartsch HH, Blossey HC, Nagel GA (1983) High-dose medroxyprogesterone acetate in metastatic breast cancer: Preliminary report on three AIO phase II trials. In: Campio L, Robustelli della Cuna G, Taylor RW (eds) Role of Medroxyprogesterone in endocrine-related tumors. Raven Press, New York, pp 85–93

    Google Scholar 

  33. Willis KJ, London DR, Ward HWC, Butt WR, Lynch SS, Rudd BT (1977) Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course. Br Med J I:425–428

    Google Scholar 

Download references

Author information

Author notes

  1. Ch. Blossey

    Present address: The Weizmann Institute of Science, Rehovot, Israel

Authors and Affiliations

  1. Zentrum für Innere Medizin, Universität Göttingen, Germany

    H. E. Wander, J. Köbberling & G. A. Nagel

Authors
  1. H. E. Wander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ch. Blossey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Köbberling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. A. Nagel
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Mit Unterstützung eines Forschungsbeitrages des Bundesministers für Jugend, Familie und Gesundheit, Kap. 1502, Tit. 685 01

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wander, H.E., Blossey, C., Köbberling, J. et al. Hochdosiertes Medroxyprogesteronacetat beim metastasierenden Mammakarzinom: Beziehung zwischen Krankheitsverlauf und Hormonprofilen. Klin Wochenschr 61, 553–560 (1983). https://doi.org/10.1007/BF01486845

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01486845

Key words

Search

Navigation